Photon buildup factors of some chemotherapy drugs


Kavaz E., Ahmadıshadbad N., Özdemir Y.

Biomedicine and Pharmacotherapy, cilt.69, ss.34-41, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 69
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/j.biopha.2014.10.031
  • Dergi Adı: Biomedicine and Pharmacotherapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.34-41
  • Anahtar Kelimeler: Buildup factor, Energy absorption, Exposure, Chemotherapy drugs, Radiotherapy, ATTENUATION COEFFICIENTS, NECK-CANCER, RADIOTHERAPY, DOXORUBICIN, CARCINOMA, HEAD, PENETRATION, PROGRESSION, ABSORPTION, RADIATION
  • Atatürk Üniversitesi Adresli: Evet

Özet

Everyday more and more people are diagnosed with some form of cancer. Some are treatable with chemotherapy alone, while others need radiotherapy and occasionally surgery. Recently, concurrent administration of chemotherapy and radiotherapy has been increasingly used in cancer treatment, leading to improvements in survival as well as quality of life. Accordingly, interaction of chemotherapy drugs with radiation will be meaningful to examine. In the present study, gamma ray energy absorption and exposure of buildup factors were computed using the five-parameter geometric progression (G-P) fitting formula for some chemotherapy drugs in the energy range 0.015-15 MeV, and for penetration depths up to 40 mean free path (mfp). The generated energy absorption (EABF) and exposure buildup factors (EBF) of chemotherapy drugs have been studied as a function of penetration depth and incident photon energy. The significant variations in EABF and EBF for chemotherapy drugs have been observed at the moderate energy region. It has been concluded that the buildup of photons is less in azathioprine and is more in vinblastine compared with other drugs. Buildup factors investigated in the present work could be useful in radiation dosimetry and therapy. (C) 2014 Elsevier Masson SAS. All rights reserved.